SI1750683T1 - Formulacije s podaljĺ anim sproĺ äśanjem - Google Patents

Formulacije s podaljĺ anim sproĺ äśanjem

Info

Publication number
SI1750683T1
SI1750683T1 SI200531678T SI200531678T SI1750683T1 SI 1750683 T1 SI1750683 T1 SI 1750683T1 SI 200531678 T SI200531678 T SI 200531678T SI 200531678 T SI200531678 T SI 200531678T SI 1750683 T1 SI1750683 T1 SI 1750683T1
Authority
SI
Slovenia
Prior art keywords
sustained release
release formulations
formulations
sustained
release
Prior art date
Application number
SI200531678T
Other languages
English (en)
Inventor
Merrill S. Goldenberg
Jian Hua Gu
Original Assignee
Amgen Inc. M/S 27-4-A, Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc. M/S 27-4-A, Amgen Inc. filed Critical Amgen Inc. M/S 27-4-A, Amgen Inc.
Publication of SI1750683T1 publication Critical patent/SI1750683T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
SI200531678T 2004-04-23 2005-04-25 Formulacije s podaljĺ anim sproĺ äśanjem SI1750683T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56524704P 2004-04-23 2004-04-23
EP05742315A EP1750683B1 (en) 2004-04-23 2005-04-25 Sustained release formulations
PCT/US2005/014254 WO2005105057A1 (en) 2004-04-23 2005-04-25 Sustained release formulations

Publications (1)

Publication Number Publication Date
SI1750683T1 true SI1750683T1 (sl) 2013-04-30

Family

ID=34967842

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200531678T SI1750683T1 (sl) 2004-04-23 2005-04-25 Formulacije s podaljĺ anim sproĺ äśanjem

Country Status (16)

Country Link
US (2) US7323169B2 (sl)
EP (1) EP1750683B1 (sl)
JP (3) JP5036533B2 (sl)
KR (1) KR101201638B1 (sl)
CN (2) CN103920162B (sl)
AU (1) AU2005237542B2 (sl)
CA (1) CA2563185C (sl)
DK (1) DK1750683T3 (sl)
ES (1) ES2400687T3 (sl)
HK (2) HK1103023A1 (sl)
IL (1) IL178596A (sl)
PL (1) PL1750683T3 (sl)
PT (1) PT1750683E (sl)
SI (1) SI1750683T1 (sl)
WO (1) WO2005105057A1 (sl)
ZA (1) ZA200609401B (sl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2400687T3 (es) * 2004-04-23 2013-04-11 Amgen Inc. Formulaciones de liberación sostenida
US20050271726A1 (en) * 2004-06-02 2005-12-08 Albert Crum Immune enhancing compositions and methods of use thereof
US7906625B2 (en) 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
US7252834B2 (en) * 2005-04-25 2007-08-07 Clemson University Research Foundation (Curf) Elastin stabilization of connective tissue
WO2007005738A2 (en) * 2005-06-30 2007-01-11 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Glp-1 pharmaceutical compositions
AU2007237163A1 (en) * 2006-02-15 2007-10-18 Gammacan Ltd. Immunoglobulins from vitiligo plasma for melanoma therapy
CA2657307A1 (en) * 2006-07-21 2008-01-24 Amgen Inc. Method of detecting and/or measuring hepcidin in a sample
US7947646B2 (en) 2007-03-06 2011-05-24 Amgen Inc. Variant activin receptor polypeptides
CA2687141C (en) 2007-05-22 2014-04-01 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
WO2009085200A2 (en) 2007-12-21 2009-07-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
EP2257274A4 (en) * 2008-02-21 2011-07-20 Vatrix Medical Inc TREATMENT OF ANEURYSMA USING A BIND WEAVE STABILIZING AGENT COMBINED WITH A DISPENSER
US20100016833A1 (en) * 2008-07-15 2010-01-21 Ogle Matthew F Devices for the Treatment of Vascular Aneurysm
US20100119605A1 (en) * 2008-11-12 2010-05-13 Isenburg Jason C Compositions for tissue stabilization
US8444624B2 (en) 2009-10-19 2013-05-21 Vatrix Medical, Inc. Vascular medical devices with sealing elements and procedures for the treatment of isolated vessel sections
US8911468B2 (en) 2011-01-31 2014-12-16 Vatrix Medical, Inc. Devices, therapeutic compositions and corresponding percutaneous treatment methods for aortic dissection
AU2012228990B2 (en) 2011-03-16 2017-04-06 Amgen Inc. Potent and selective inhibitors of Nav1.3 and Nav1.7
WO2012158944A1 (en) 2011-05-18 2012-11-22 Vatrix Medical, Inc. Coated balloons for blood vessel stabilization
AU2012364736A1 (en) * 2011-12-19 2014-07-24 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
EP2935311B1 (en) 2012-12-20 2021-03-31 Amgen Inc. Apj receptor agonists and uses thereof
JP2016508504A (ja) 2013-02-01 2016-03-22 サンタ マリア バイオセラピューティクス インコーポレイテッド 対象に対する抗アクチビン−ａ化合物の投与
UY35397A (es) 2013-03-12 2014-10-31 Amgen Inc INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7
ES2950789T3 (es) 2014-06-10 2023-10-13 Amgen Inc Polipéptidos de apelina
AR101476A1 (es) 2014-08-07 2016-12-21 Acerta Pharma Bv Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk)
WO2018226383A1 (en) * 2017-06-07 2018-12-13 Egy-Nano Pharma, Lp Oral prolonged drug delivery platforms
CN112770714B (zh) 2018-08-03 2024-05-24 奈克塞罗医学有限公司 纯化的五没食子酰葡萄糖和递送装置
WO2020227437A1 (en) 2019-05-06 2020-11-12 Axial Biotherapeutics, Inc. Sustained release solid dosage forms for modulating the colonic microbiome

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2849370A (en) * 1953-06-04 1958-08-26 Novo Terapeutisk Labortorium A Injectable insulin preparations with protracted effect and process of producing same
GB929406A (en) 1958-12-22 1963-06-19 Upjohn Co A process for the production of encapsulated material
CH498653A (fr) 1968-03-29 1970-11-15 Kobayashi Takehiko Procédé d'encapsulation de matières hydrophobes
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5151265A (en) * 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
US5019400A (en) * 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
AU5171293A (en) * 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
JP2744572B2 (ja) * 1993-02-17 1998-04-28 鐘紡株式会社 ポリフェノール化合物含有皮膚外用剤組成物の変色防止方法
JPH06345668A (ja) * 1993-06-07 1994-12-20 Shibayagi:Kk 感染防御組成物およびその用途
US5922253A (en) * 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
CA2230494A1 (en) * 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics Inc. Composition for sustained release of an agent
AU4414497A (en) 1996-09-13 1998-04-02 University Technology Corporation Biocompatible cationic detergents and uses therefor
US20030190307A1 (en) * 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
US6531154B1 (en) * 1997-06-10 2003-03-11 Brown University Research Foundation Modulated release from biocompatible polymers
BR9811478A (pt) * 1997-07-23 2000-08-15 Perio Prod Ltd Composições de polìmero-ácido tânico para a liberação controlada de agentes farmacêuticos particularmente na cavidade oral
US6180666B1 (en) 1997-09-05 2001-01-30 Anmax, Inc. Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds
US5962522A (en) * 1997-09-05 1999-10-05 Avmax, Inc. Propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
US6613358B2 (en) * 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
DE69921636T2 (de) * 1998-04-20 2005-11-03 Genzyme Corp., Cambridge Medikamentöse verabreichung von proteinen aus polymergemischen
JP2000080027A (ja) * 1998-09-02 2000-03-21 Taiyo Kagaku Co Ltd 徐放性製剤
US6428818B1 (en) * 1999-03-30 2002-08-06 Purdue Research Foundation Tea catechin formulations and processes for making same
CA2389304A1 (en) 1999-11-01 2001-05-10 Corinne S. Lengsfeld Compositions and methods for controlled-release delivery and increased potency of pharmaceuticals via hydrophobic ion-pairing
US6713506B2 (en) * 2000-10-11 2004-03-30 University Of South Florida Tea polyphenol esters and analogs thereof for cancer prevention and treatment
US6759064B2 (en) * 2001-02-22 2004-07-06 Purdue Research Foundation Compositions based on vanilloid-catechin synergies for prevention and treatment of cancer
JP5013152B2 (ja) 2001-02-28 2012-08-29 株式会社ビーエムジー 蛋白質複合体形成剤
US20040142048A1 (en) * 2002-02-22 2004-07-22 Morre Dorothy M. Compositions based on proanthocyanadin-catechin synergies for prevention and treatment of cancer
CN1668212A (zh) * 2002-07-26 2005-09-14 帝斯曼知识产权资产管理有限公司 包含乳铁蛋白的组合物
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US7605120B2 (en) * 2003-10-22 2009-10-20 Amgen Inc. Antagonists of the brandykinin B1 receptor
ES2400687T3 (es) * 2004-04-23 2013-04-11 Amgen Inc. Formulaciones de liberación sostenida

Also Published As

Publication number Publication date
AU2005237542B2 (en) 2009-12-17
PT1750683E (pt) 2013-01-25
CN103920162B (zh) 2017-07-11
ES2400687T3 (es) 2013-04-11
CN1997356A (zh) 2007-07-11
JP5829870B2 (ja) 2015-12-09
KR20070026457A (ko) 2007-03-08
US20070292506A1 (en) 2007-12-20
CN103920162A (zh) 2014-07-16
HK1103023A1 (en) 2007-12-14
AU2005237542A1 (en) 2005-11-10
US7732399B2 (en) 2010-06-08
ZA200609401B (en) 2008-05-28
PL1750683T3 (pl) 2013-05-31
JP5036533B2 (ja) 2012-09-26
CA2563185A1 (en) 2005-11-10
IL178596A (en) 2012-06-28
DK1750683T3 (da) 2013-04-15
EP1750683A1 (en) 2007-02-14
WO2005105057A1 (en) 2005-11-10
JP2012046520A (ja) 2012-03-08
KR101201638B1 (ko) 2012-11-15
US20050271722A1 (en) 2005-12-08
CA2563185C (en) 2010-04-20
EP1750683B1 (en) 2013-01-09
US7323169B2 (en) 2008-01-29
HK1200092A1 (en) 2015-07-31
JP2007534698A (ja) 2007-11-29
IL178596A0 (en) 2007-02-11
JP2012036194A (ja) 2012-02-23

Similar Documents

Publication Publication Date Title
HK1200092A1 (en) Sustained release formulations
IL184460A0 (en) Sustained release pharmaeutical formulations
EP1765385A4 (en) IMPORTS COMPOSITION WITH DELAYED RELEASE
EP1714643A4 (en) PREPARATION WITH DELAYED RELEASE
GB2424581B (en) Formulations
IL181265A0 (en) Stabilizing formulations
IL188964A0 (en) Sustained drug release composition
GB0406819D0 (en) Controlled release compositions
EP1909584A4 (en) PRENYLFLAVONOID FORMULATIONS
EP1802346A4 (en) PHARMACEUTICAL COMPOSITION WITH EXTENDED RELEASE
ZA200707654B (en) Formulations
EP1951693A4 (en) SOLID FORMULATIONS
IL177328A0 (en) Controlled release formulations
GB0406048D0 (en) Drug formulations
GB0417226D0 (en) Formulations
GB0417248D0 (en) Formulations
IL179208A0 (en) Intereferon formulations
GB0426294D0 (en) Novel formulations
GB0420820D0 (en) Novel formulations
GB0426292D0 (en) Novel formulations
GB0427247D0 (en) Novel formulations
GB0420821D0 (en) Novel formulations
GB0427244D0 (en) Novel formulations
GB0420817D0 (en) Novel formulations
GB0427245D0 (en) Novel formulations